Table 15 Assessment of responsiveness of the EQ-5D-3L and the EQ-5D-5L measures to changes in the VAS, for the subgroup in Switzerland
EQ-5D-3L at 6 months (mean) | EQ-5D-3L at 12 months (mean) | Difference between 12 and 6 months EQ-5D-3L (95% CI) | Effect size (Cohen’s D)a | n | % reporting 3L score increase | |
|---|---|---|---|---|---|---|
3L-VAS | ||||||
Improved | 0.92 | 0.93 | 0.01 (− 0.03 to 0.05) | 0.15 | 10 | 30 |
No change | 0.87 | 0.81 | − 0.06 (− 0.19 to 0.07) | − 0.22 | 25 | 24 |
Worsened | 0.85 | 0.84 | − 0.01 (− 0.08 to 0.06) | − 0.06 | 20 | 15 |
EQ-5D-5L at 6 months (mean) | EQ-5D-5L at 12 months (mean) | Difference between 12 and 6 months EQ-5D-5L (95% CI) | Effect size (Cohen’s D) | n | % reporting 5L score increase | |
|---|---|---|---|---|---|---|
5L-VAS | ||||||
Improved | 0.90 | 0.91 | 0.01 (− 0.02 to 0.04) | 0.14 | 10 | 30 |
No change | 0.83 | 0.81 | − 0.02 (− 0.10 to 0.07) | − 0.06 | 25 | 28 |
Worsened | 0.84 | 0.85 | 0.01 (− 0.06 to 0.08) | 0.05 | 20 | 20 |